We are pleased that a delegation from the study team had the opportunity to present EMPASTONE to an international audience of experts at the International Symposium on Urolithiasis (ISU) in Chicago in early October 2026. This allowed us to raise…
So far, a total of 46 participants have joined the EMPASTONE study. A big thank you to everyone who has already agreed to take part! The study sites in Aarau, Baden, Basel, Bern, Chur, Geneva, Lausanne, St. Gallen and Zurich…
We are pleased to have reached an important milestone in our clinical trial: the first patient has been enrolled in EMPASTONE at the study site in Bern, Switzerland! We look forward to recruiting many more patients in the coming months.…
EMPASTONE uses a study drug that is not authorised for the prevention of kidney stones. Authorisation from the Swiss medicines regulatory authority, Swissmedic, is therefore required in order to conduct the trial in Switzerland. Following a thorough review, Swissmedic approved…
The Bern Ethics Committee reviewed the study and approved it in January 2026. This confirms that the study meets the ethical requirements and may be conducted.
In June 2025, the Swiss Nationanal Science Foundation (SNSF) announced that it would fund the EMPASTONE study. The study is being funded under the IICT programme (‘Investigator Initiated Clinical Trials’). Of a total of 47 applications, 6 (12%) were approved.